Fasenra pen 30 MG/mlml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRW5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,963
Award facts
- Contract value 100% obligated
- $14,962.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,962.50 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/ml on January 29, 2026. This firm fixed-price delivery order, with an ultimate completion date of January 30, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the Department of Defense's pharmaceutical supply chain, specializing in distributing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to federal agencies.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and ultimate completion through December 31, 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy establishing multiple regional prime vendor contractors to provide comprehensive pharmaceutical support for Department of Defense healthcare operations globally, with DMS Pharmaceutical Group positioned to fulfill diverse and specialized pharmaceutical requirements for military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FCRW5?
SPE2DR26FCRW5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FCRW5 worth?
The government has obligated $14,963 on SPE2DR26FCRW5.
Is contract SPE2DR26FCRW5 an order under another contract?
Yes. SPE2DR26FCRW5 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRW5 competed?
The extent of competition for SPE2DR26FCRW5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award